Loading...
•
Jun 30, 2024
Coherus Q2 2024 Earnings Report
Coherus reported financial results for the second quarter of 2024
Key Takeaways
Coherus BioSciences reported net revenue of $65.0 million for Q2 2024, including $50.9 million from UDENYCA, $3.8 million from LOQTORZI, $3.8 million from YUSIMRY, and $6.5 million from other revenue. The company's net loss for the quarter was $12.9 million, or $(0.11) per share.
Net revenue for Q2 2024 was $65.0 million.
UDENYCA net product sales were $50.9 million in Q2 2024, a 60% increase compared to Q2 2023.
LOQTORZI net sales in Q2 2024 were $3.8 million, with new patient uptake primarily in relapsed locally advanced and 1L metastatic disease.
An IND application for CHS-1000 was filed with the FDA in Q2 2024 and received clearance.
Revenue by Segment
Forward Guidance
Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...